Baxter International Inc, AesRx deal

Baxter acquired Orphan disease play AesRx, gaining Aes-103, which AesRx was developing with funding from NIH’s National Center for Advancing Translational Sciences (NCATS). Financial terms of AesRx’s acquisition are undisclosed but include an upfront payment and development, regulatory and commercial milestones. Aes-103 - an aromatic aldehyde that increases the affinity of sickle hemoglobin for oxygen - is in Phase II testing to treat sickle cell disease. AesRx gained rights to Aes-103 from Virginia Commonwealth University. Baxter also gained AesRx’s Aes-210, a muco-adhesive clotrimazole gel that is in Phase II testing for pouchitis. ...